The present invention relates to the use of chicoric acid and/or at least one of these metabolites selected among mono-caffeoyl-tartaric acid and/or m-hydroxyphenylpropionic acid, and/or 4-vinylcatechol and/or 4-ethylcatechol for manufacturing a composition intended for prevention or treatment in an insulin-resistant patient or hypoinsulinemia and/or associated pathologies.